Cargando…

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes

OBJECTIVE: We investigated the association of plasma amyloid beta (Abeta)40, Abeta42, and total tau (tTau) with the presence of Alzheimer pathological changes in cognitively normal individuals with subjective cognitive decline (SCD). METHODS: We included 248 subjects with SCD (61 ± 9 years, 42% fema...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verberk, Inge M. W., Slot, Rosalinde E., Verfaillie, Sander C. J., Heijst, Hans, Prins, Niels D., van Berckel, Bart N. M., Scheltens, Philip, Teunissen, Charlotte E., van der Flier, Wiesje M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282982/ https://www.ncbi.nlm.nih.gov/pubmed/30196548 http://dx.doi.org/10.1002/ana.25334

Ejemplares similares

A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline
por: Verfaillie, Sander C. J., et al.
Publicado: (2018)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Combination of plasma amyloid beta((1-42/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
por: Verberk, Inge M. W., et al.
Publicado: (2020)

Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project
por: Verfaillie, Sander C. J., et al.
Publicado: (2019)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results
por: Slot, Rosalinde E. R., et al.
Publicado: (2018)

Computer-assisted prediction of clinical progression in the earliest stages of AD
por: Rhodius-Meester, Hanneke F.M., et al.
Publicado: (2018)

ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project
por: Ebenau, Jarith L., et al.
Publicado: (2020)

Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease
por: Thijssen, Elisabeth H., et al.
Publicado: (2021)

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Lumbar puncture in patients with neurologic conditions
por: Babapour Mofrad, Rosha, et al.
Publicado: (2017)

Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status
por: Babapour Mofrad, Rosha, et al.
Publicado: (2021)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
por: Stockmann, Julia, et al.
Publicado: (2020)

Risk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score
por: Ebenau, Jarith L., et al.
Publicado: (2021)

Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
por: Stockmann, Julia, et al.
Publicado: (2021)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Cerebral perfusion in the predementia stages of Alzheimer’s disease
por: Binnewijzend, Maja A. A., et al.
Publicado: (2015)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
por: Wolters, Emma E., et al.
Publicado: (2020)

Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

Amyloid imaging in clinical trials
por: Ossenkoppele, Rik, et al.
Publicado: (2013)

Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia
por: van Wijk, Nick, et al.
Publicado: (2017)

Amyloid imaging in prodromal Alzheimer's disease
por: Ossenkoppele, Rik, et al.
Publicado: (2011)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project
por: Wesselman, Linda M. P., et al.
Publicado: (2019)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Amyloid‐β PET and CSF in an autopsy‐confirmed cohort
por: Reimand, Juhan, et al.
Publicado: (2020)

Plasma biomarkers predict amyloid pathology in cognitively normal monozygotic twins after 10 years
por: den Braber, Anouk, et al.
Publicado: (2023)

Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?
por: den Haan, Jurre, et al.
Publicado: (2019)

Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [(18)F]Flortaucipir and [(18)F]Florbetapir Brain PET Studies
por: de Vries, Bart M., et al.
Publicado: (2021)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Hippocampal [(18)F]flortaucipir BP(ND) corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
por: Wolters, Emma E, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hhnhbo0dqbvv70coboegeinbc5